Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by pabalooon Sep 30, 2020 2:02am
67 Views
Post# 31640218

RE:RE:RE:RE:RE:RE:distribution deals next week?

RE:RE:RE:RE:RE:RE:distribution deals next week?Royalty rate is not discussed pre or after generic launch. This means it is exactly the same why would it be different? There is zero reason! If generic takes a big bite both parties suffer period. The deal with Sun expires next year they can renegotiate with Cipher at that time. If not cipher can sell the rights to the highest bidder or make another deal with someone who might do a better job than Sun or do what there doing in Canada and just enjoy the branding which alone would bring in more than Sun is paying them. Like I said before Activis appears that they are NOT going to launch a generic which is worth millions to Cipher and Sun. It maybe Covid delaying it or the cost to develop was too high to justify. Generics always move in when a drug has strong market share luckily Absorica has steadily lost market share since 2013 when Activis wanted to launch its generic version. 
Bullboard Posts